New Scientific Advisory Board

BioMark would like to introduce and welcome 2 new members to its scientific advisory board. The new members are:

  • Dr. Samudra Dissanayake, Director Strategic Initiatives and Business Development Health-Tech-Connex
    Dr. Dissanayake has been an important contributor in the development of BioMark’s technology platform for cancer screening, response to treatment and cancer treatment. Dr. Dissanayake role would be to advise the management team on how to develop critical relationships with agencies and principal investigators both in USA and Canada.
  • Dr. Horacio Bach, PhD, Adjunct Professor, Faculty Manager of IIRC Antibody Engineering and Proteomics Facilities, Department of Medicine, Div. of Infectious Diseases, University of British Columbia
    Dr. Bach’s expertise would greatly increases BioMark’s confidence in internalization studies related to an enzyme of interest, shed better understanding on mechanism of action and to conduct detailed receptor studies prior to commencing in vivo studies for select BioMark therapeutic drug candidates.
Share this post:
Share on facebook
Share on twitter
Share on linkedin
Share on email
Categories
Archives

Sign up for the latest Biomark news

No paperwork, no hassle. We keep things digital, easy and regular.

*Zero Spam Policy. You will need to confirm your email address to receive our news to your inbox.

BioMark Diagnostics Inc.
CSE: BUX
OTC: BMKDF
FSE: 20B
Investors

Related articles ...

© 2021 BioMark Diagnostics Inc. All Rights Reserved. BioMark’s mission is to provide universal access to a new paradigm in cancer diagnostics using metabolomics.